SUMMARY: This episode provides a deep and wide-ranging discussion on the intersection of artificial intelligence, biotechnology, and decentralized computing networks like Bittensor. The central theme is how AI-driven innovation is poised to radically transform fields such as genetic engineering, drug discovery, software development, and ultimately human evolution. It emphasizes the promise and challenges of engineering…
Decentralized AI is often framed as an alternative to centralized research labs, but in practice most systems struggle to move beyond theory. Benchmarks are published, models are trained, and incentives are discussed, yet the gap between virtual results and real-world impact remains wide. NOVA, a decentralized drug discovery platform built on Bittensor, is attempting to…
Drug discovery starts with an overwhelming problem. There are billions of possible molecules, but only a tiny fraction will ever become real medicines. The challenge is not just finding molecules that bind to a target. It is finding the right molecules early enough, before time and capital are wasted downstream. This is the problem NOVA…
Drug discovery is entering a new era where AI, collective intelligence, and decentralised compute are beginning to reshape how early research is done. Metanova Labs and DiaGen AI announced a milestone joint venture LOI (Letter of Intent) that will push this shift forward by building an automated, multi-objective hit picking system designed to score, evaluate,…
When decentralized artificial intelligence meets decentralized science, the result can be a completely new way of solving problems that have resisted progress for decades. NOVA, grounded on Bittensor’s Subnet 68 and created by Metanova Labs, is one of the clearest real world examples of what happens when these two sectors converge. It shows how open…
The Metanova Labs team, Micaela Bazo and Penn Apdr, discuss how their subnet is decentralizing drug discovery through AI-driven molecular screening. They explore upstream determinants of health, neuroplasticity, and strategic therapeutic targets like monoamine transporters and HDACs. The conversation also covers intellectual property in decentralized science, miner incentives, and the launch of NOVA Blueprint as…
Bringing a new drug to market is notoriously slow and expensive. Recent analyses estimate that the median cost — including failures — sits around $985 million, while the average exceeds $1.3 billion per approved drug. Even during the COVID-19 pandemic, governments spent tens of billions of dollars on vaccine development, revealing how resource-intensive and centralized…
